@kristinaventimiglia's Zepbound hunger claims, fact-checked

What did @kristinaventimiglia actually say?

She said she's a few days into her first Zepbound injection and has "like zero hunger," which she calls bizarre given her self-described obsession with food. She's forcing herself to eat small things, celery with hummus, a protein salad, and is asking her audience whether this is normal and whether it will continue. Crucially, she's not making a medical claim. She's describing a personal experience and crowdsourcing guidance from other users.

That distinction matters. This isn't someone telling her 159,000 viewers that Zepbound will suppress their appetite this fast. She's expressing genuine surprise and uncertainty. The video reads more like a patient diary entry than a health tutorial, and it should be assessed that way.

Does the science back this up?

Yes, substantially. Tirzepatide, the active ingredient in Zepbound, does produce rapid appetite suppression that can show up within the first few days of the starting dose. This isn't a placebo effect or influencer hype.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced significantly greater weight reduction than placebo, with appetite reduction being one of the primary drivers. Mechanistically, tirzepatide slows gastric emptying and acts on hypothalamic satiety centers. A 2023 study by Frias et al. in Diabetes Care confirmed that reduced appetite scores appeared early in the treatment timeline, not just after dose escalation. So her experience of near-zero hunger in week one is biologically plausible and well-supported. She's not imagining it.

What did they get right or wrong?

She got the core experience right. Early and pronounced appetite suppression on tirzepatide is real, documented, and not unusual. Credit where it's due.

Where she stumbles, without quite realizing it, is the eating behavior she's defaulting to. Eating only celery and hummus and skipping meals because she's not hungry is not an optimal approach on a GLP-1 or GIP/GLP-1 medication. When total caloric intake drops too low too fast, patients risk muscle loss alongside fat loss. The SURMOUNT trials used structured dietary counseling alongside medication for good reason. Researchers like Hall and Guo (2017, Obesity Reviews) have documented that very low intake without adequate protein accelerates lean mass loss during rapid weight reduction. She isn't wrong about what she's feeling. But the implicit suggestion that eating very little is fine because you're "not hungry" is where the real clinical gap shows up.

What should you actually know?

Appetite suppression this early and this strong is common enough that clinicians expect it, but it requires active management, not passive acceptance.

• Tirzepatide's dual mechanism makes appetite suppression more pronounced than semaglutide-only drugs for many patients, which is why the "I'm never hungry" experience shows up so frequently in early Zepbound users.
• Not eating enough protein during GLP-1 or dual-agonist therapy is a documented clinical problem. Most prescribing guidelines recommend at least 1.2 grams of protein per kilogram of body weight to preserve muscle during weight loss.
• Hummus is not a bad food. Her aside that "hummus isn't the best" is unnecessary self-criticism. It contains protein and fiber and is a reasonable snack. Processed snacks marketed as "diet food" are often worse.
• The question she's actually asking, will this continue, is one she should be directing to her prescriber, not TikTok. Appetite often partially returns as the body adjusts, but patterns vary significantly by individual and by dose.
• If you recognize yourself in this video, talk to the clinician who prescribed your medication about minimum intake targets. Skipping meals because suppression is strong is not a feature to lean into without clinical oversight.

The bottom line

Kristina's experience is real and scientifically grounded. Tirzepatide produces fast, significant appetite suppression and early-week results like hers are not anomalous. But the behavior that follows, eating almost nothing and treating suppression as permission to skip meals, is where clinical risk enters the picture. This video is harmless as a personal account. As unintentional guidance for 159,000 viewers, some of whom may be newly starting the same drug, it's missing the part where someone tells you that "not hungry" doesn't mean "don't need to eat."